L'intérêt à découvert pour Spyre Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Spyre Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Spyre Therapeutics (NASDAQ:SYRE) Stock, Rapport sur les intérêts à découvert

Spyre Therapeutics

Aeglea BioTherapeutics

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Spyre Therapeutics Inc

News

Guidance

TopBuild Sees FY25 Sales Of $5.05B-$5.35B Vs. $5.465B and Adj EBITDA Of $925M-$1.075B

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA&#xAE; (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 23, 2025.
The sBLA is based on data from the Phase 3 KEYNOTE-689 trial. Results from a pre-specified first interim analysis, which will be presented at an upcoming medical meeting, showed that in patients with resectable LA-HNSCC, the KEYTRUDA perioperative treatment regimen demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) compared to adjuvant radiotherapy (with or without cisplatin) alone. The study also showed a statistically significant improvement in major pathological response (mPR), a key secondary endpoint, for patients in the KEYTRUDA arm compared with adjuvant radiotherapy alone. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.

Government

Regulations

Merck's Keytruda Gains FDA Priority Review for Head and Neck Cancer Treatment

Barclays analyst Nicholas Campanella maintains OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Equal-Weight and raises the price target from $42 to $44.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on OGE Energy, Raises Price Target to $44

General

Castellum GTMR Subsidiary Selected As Special Compartmented Information Multiple Award Contract (SCI MAC) Vendor

WIIM

DNUT

Krispy Kreme shares are trading lower after the company reported worse-than-expected Q4 earnings and issued weak FY25 guidance.

TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) reported quarterly earnings of $5.13 per share which beat the analyst consensus estimate of $5.05 by 1.58 percent. This is a 9.38 percent increase over earnings of $4.69 per share from the same period last year. The company reported quarterly sales of $1.31 billion which met the analyst consensus estimate. This is a 2.04 percent increase over sales of $1.29 billion the same period last year.

Earnings

Earnings Beats

TopBuild Q4 2024 Adj EPS $5.13 Beats $5.05 Estimate, Sales $1.31B Inline

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and maintains $17 price target.

Reiteration

RIOT

HC Wainwright & Co. Reiterates Buy on Riot Platforms, Maintains $17 Price Target

Barclays analyst Nicholas Campanella maintains PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Equal-Weight and raises the price target from $33 to $36.

Barclays Maintains Equal-Weight on PPL, Raises Price Target to $36

Health Care

Eli Lilly Launches 7.5 mg And 10 mg Zepbound Single-Dose Vials For $499 With The New Zepbound Self Pay Journey Program

Krispy Kreme Sees FY25 Revenue $1.55B-$1.65B vs. $1.764B Est., Adj. EPS $0.04-$0.08 vs. $0.30 Est.

Earnings Misses

Krispy Kreme Q4 2024 Adj. EPS $0.01 Misses $0.10 Estimate

Krispy Kreme Q4 Sales $404M Miss $415.450M Estimate

Needham analyst James Ricchiuti maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $34 to $37.

FARO

Needham Maintains Buy on Faro Technologies, Raises Price Target to $37

On Thursday, Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) said it supports the U.S. Department of Health and Human Services&#8217; focus on vaccine efficacy transparency, emphasizing the need for accessible information to aid informed health decisions.
The company underscores the role of transparency in understanding vaccine effectiveness and the impact of individual immune responses on vaccination outcomes.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41484229/exclusive-virax-biolabs-inks-distribution-pact-to-commercialize-immuneselect-profiling-solutions-in" rel="noreferrer noopener">EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland</a>
Earlier this month, the U.S. Senate voted to confirm Robert F. Kennedy Jr. as the head of the Department of&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health" rel="noreferrer noopener">Health and Human Services.&nbsp;</a>
The Senate voted 52 to 48 to confirm Kennedy as health secretary, with Sen.&nbsp;Mitch McConnell as the only Republican who voted &#8220;no.&#8221; All Democrats voted against the nomination.&nbsp;
As secretary of health, Kennedy will oversee several critical health agencies, including the Food and Drug Administration, the Centers for Disease Control and Prevention, and the Centers for Medicare and Medicaid Services.&nbsp;
Kennedy has been an outspoken skeptic on vaccines for decades. As a player in advancing vaccine transparency, Virax Biolabs collaborates with vaccine developers to provide research-based tools for assessing efficacy and long-term immune protection.
Its technology supports comprehensive immune profiling, aiding protective immunity and T-cell dysfunction research. By leveraging its platform, the company aims to enhance the understanding of immune responses post-vaccination.
&#8220;As this new administration appears to enter a new era of vaccine transparency, we believe Virax Biolabs is well-positioned to provide additional critical, data-driven insights on vaccine efficacy to support existing and future vaccine development,&#8221; said James Foster, Chief Executive Officer of Virax Biolabs. &#8220;We are fully aligned in supporting Public Health initiatives around Vaccine Efficacy Testing.&#8221;
In January, Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) entered into a distribution agreement with Virax Biolabs to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across various major European markets and certain Gulf <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/ac42945842/cosmos-health-secures-exclusive-distribution-agreement-with-virax-biolabs-for-avian-influenza-vir" rel="noreferrer noopener">Cooperation Council (GCC) countries</a>.
Price Action: VRAX stock was down 1.73% at $1.70 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43921655/generic-drug-maker-amneal-pharmaceuticals-is-positioned-to-growth-well-ahead-of-peers-analyst-upgrades-stock" target="_blank" rel="noreferrer noopener">Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock</a></li>
</ul>

Market-Moving Exclusives

Exclusives

COSM

VRAX

EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency

EXCLUSIVE: Virax Biolabs Tells Benzinga Co. Believes Its Tech Fits RFK Jr.'s Department Of Health & Human Services Goals On Vaccine Transparency

Barclays analyst Nicholas Campanella maintains Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Overweight and raises the price target from $42 to $48.

Barclays Maintains Overweight on Exelon, Raises Price Target to $48

Outlook for Fiscal 2025 and Guidance Policy Strong, core recurring business provides solid foundation for 2025:
<ul>
<li>Revenue of $2.55 - $2.65 billion, up low-mid single digits
<ul>
<li>Global same-store sales up low-single-digits</li>
<li>Higher product sales, driven by sustainable instant ticket services growth</li>
<li>H1'25 impacted by an estimated $40 - $50 million from lower U.S. Multi-state Jackpot activity and associated LMA incentives, accounting for lower expected revenue in Q1'25 versus Q1'24</li>
</ul>
</li>
<li>Adjusted EBITDA of $1.10 - $1.15 billion
<ul>
<li>Flow-through of lower U.S. Multi-state Jackpot activity and associated&nbsp;LMA incentives referenced above</li>
<li>$25 million of increased investment in the business (contract&nbsp;rebids and extensions, cloud-based solutions, network optimization), which are mostly concentrated in H1'25 and are expected to deliver future capital expenditure efficiencies</li>
<li>Q1'25 Adjusted EBITDA down approximately $70 million, primarily on lower U.S. Multi-state Jackpot activity and associated LMA incentives, in addition to unfavorable product mix and investment in the business; in the balance of the year, Adjusted EBITDA is aligned with the prior year, including growth in H2'25</li>
</ul>
</li>
<li>Net cash used in operating activities of approximately $300 million
<ul>
<li>Includes €800 million (approximately $850 million) related to first two installments of Italy Lotto upfront license fee (reflects 100% consolidation of Italy joint venture; minority partner contributions representing their pro rata share are recorded in cash flows from financing activities)</li>
<li>Ex-Lotto license fee and compared to FY'24, cash flow performance impacted approximately one-third by the lower forecasted Adjusted EBITDA and two-thirds by the timing of certain working capital items</li>
</ul>
</li>
<li>Capital expenditures of approximately $450 million; reflects increased investments related to contract wins, extensions, and upcoming bids</li>
</ul>

Intl Game Tech Expects FY25 Revenue Of $2.55B-$2.65B Vs $2.55B Est

TD Securities analyst Andrew Charles initiates coverage on Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Hold rating and announces Price Target of $72.

Initiation

KRUS

TD Securities Initiates Coverage On Kura Sushi USA with Hold Rating, Announces Price Target of $72

Barclays analyst Matthew Bouley maintains Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Equal-Weight and raises the price target from $7 to $9.

COMP

Barclays Maintains Equal-Weight on Compass, Raises Price Target to $9

Intl Game Tech Q4 2024 Adj. EPS $0.22 Misses $0.37 Estimate, Sales $651.000M Miss $657.835M Estimate

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Comments

Spyre Therapeutics

Intérêt court

Spyre Therapeutics (NASDAQ:SYRE) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL